REVATIS VET
The computed 12-month bankruptcy probability of REVATIS VET is 1.2% (low). The 2025 annual accounts show equity of €483k and a net result of €-112k. Its solvency ranks better than 83% of 873 sector peers (fiscal year 2025). The company has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €483k |
| Net result | €-112k |
| Better than sector | 83% |
| Active | 1 yrs |
Strong profile, led by solvency.
Computed on 4 of 5 axes. Not measured: growth. An unmeasured axis is not a zero: no data was read for it.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 78.6% | 35.1% | |
| Net result | €-112k | €10k | |
| Equity | €483k | €40k | |
| Gross operating margin | €3k | €32k | |
| Total assets | €615k | €133k |
| Fiscal year | 2025 |
|---|---|
| Deposit | micro |
| Revenue | - |
| EBITDA | €3k |
| Net profit | €-112k |
| Cash flow | €3k |
| Staff costs | - |
| Income taxes | - |
| Dividends | - |
| Total assets | €615k |
| Equity | €483k |
| Debt | €132k |
| of which ≤ 1y | €131k |
| of which > 1y | - |
| Working capital | €210k |
| Employees (FTE) | - |
| 2025 | |
|---|---|
| Current ratio | 2.59 |
| Quick ratio | 1.04 |
| Working capital ratio | 34.1% |
| Solvency | 78.6% |
| Debt / equity | 0.27 |
| Long-term debt ratio | - |
| Interest coverage | 9.29 |
| Gross margin | - |
| Net margin | - |
| ROA | -18.3% |
| ROE | -23.3% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
Full annual accounts (23 line items)
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €615k |
| Fixed assets | 21/28 | €269k |
| Formation expenses | 20 | €5k |
| Intangible fixed assets | 21 | €266k |
| Tangible fixed assets | 22/27 | €2k |
| Financial fixed assets | 28 | €750 |
| Current assets | 29/58 | €341k |
| Stocks & contracts in progress | 3 | €204k |
| Amounts receivable within one year | 40/41 | €65k |
| Cash & bank | 54/58 | €71k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €615k |
| Equity | 10/15 | €483k |
| Contributions / capital | 10/11 | €595k |
| Accumulated profits (losses) | 14 | €-112k |
| Amounts payable | 17/49 | €132k |
| Amounts payable within one year | 42/48 | €131k |
| Trade debts payable within one year | 44 | €56k |
| Income statement | ||
| Gross operating margin | 9900 | €3k |
| Operating result | 9901 | €-112k |
| Financial charges | 65 | €346 |
| Result before taxes | 9903 | €-112k |
| Net result for the period | 9904 | €-112k |
| Result to be appropriated | 9905 | €-112k |
-
BOECKX Frederic Jan RenéDirectorState Gazette act 24456781 (30-12-2024)Current30-12-2024 → present
-
CEUSTERS Justine Denise Jeanne JoséphineDirectorState Gazette act 24456781 (30-12-2024)Current30-12-2024 → present
| NACE primary | Groothandel in farmaceutische en medische artikelen(46460) |
| Legal form | Private limited company(610) |
| Incorporation | 04-11-2024 |
| Status | Active |
| Postal code | 6900 |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
We know of 4 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
30-12-2024 Capital increase of €589,891 to €595,491
- €5.600 → €595.491
Technical details
{
"events": [
{
"kind": "apport_nature",
"after_eur": 595491.0,
"delta_eur": 589891.0,
"before_eur": 5600.0,
"subscribers": [
{
"kbo": "0541.682.642",
"rrn": null,
"kind": "org",
"name": "REVATIS",
"share_class": "C",
"liberation_pct": 100.0,
"contribution_kind": "branche_d_activites",
"n_shares_subscribed": 14400,
"contribution_amount_eur": 589891.0
}
],
"share_emission": {
"agio_eur": null,
"share_form": "nominal",
"share_class": "C",
"n_new_shares": 14400,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "branche_d_activites",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_apports_non_appeles"
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Ariane DENIS",
"firm_city": null,
"firm_name": null,
"office_city": "Li\u00E8ge",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2024-12-30",
"filing_date": "2024-12-26",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "assembl\u00E9e_generale_extraordinaire",
"act_date": "2024-12-20",
"unanimous": true,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "1015.868.627",
"name_full": "REVATIS VET",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"exp\u00E9dition du proc\u00E8s-verbal du 20 d\u00E9cembre 2024",
"la coordination des statuts",
"les rapports de l\u0027organe d\u0027administration et du R\u00E9viseur",
"le projet d\u0027apport de branche d\u0027activit\u00E9",
"la preuve de son d\u00E9p\u00F4t",
"trois procurations"
],
"shareholders_after": [],
"share_classes_after": [
{
"n_shares": 2000,
"class_name": "A",
"capital_share_eur": null,
"voting_rights_per_share": null
},
{
"n_shares": 3600,
"class_name": "B",
"capital_share_eur": null,
"voting_rights_per_share": null
},
{
"n_shares": 14400,
"class_name": "C",
"capital_share_eur": null,
"voting_rights_per_share": null
}
]
}22-11-2024 Publication in the Belgian Official Gazette, Miscellaneous
Technical details
{
"stage": "proposal",
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": "Li\u00E8ge",
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": "2024-11-22",
"filing_date": "2013-10-31",
"act_kind_objet": "D\u00E9p\u00F4t du projet d\u0027apport de branche d\u0027activit\u00E9, \u00E9tabli conform\u00E9ment aux"
},
"decision": {
"body": "notarieel_alleen",
"act_date": "2024-11-06",
"unanimous": null
},
"conversion": null,
"detected_kind": "branch_contribution",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0541.682.642",
"name": "RevaTis",
"role": "contributor",
"address": "Rue de la Science, 8 \u00E0 6900 Aye",
"is_foreign": false,
"legal_form": "SA",
"is_new_company": false,
"jurisdiction_country": null
},
{
"kbo": "1015.868.627",
"name": "RevaTis Vet",
"role": "recipient",
"address": "Rue de la Science, 8 \u00E0 6900 Aye",
"is_foreign": false,
"legal_form": "SRL",
"is_new_company": false,
"jurisdiction_country": null
}
],
"exchange_ratio": null,
"legal_articles": [
"12:10",
"12:11",
"12:93"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": "2024-06-30",
"exchange_ratio_text": null,
"new_shares_issued_n": null,
"real_estate_included": true,
"patrimony_description": "L\u0027apport de branche d\u0027activit\u00E9s comprend l\u0027ensemble des actifs, passifs, droits et engagements li\u00E9s \u00E0 la branche d\u0027activit\u00E9 commercialisation de produits de m\u00E9decine r\u00E9g\u00E9n\u00E9rative v\u00E9t\u00E9rinaire et la R\u0026D y aff\u00E9rente en biotechnologie v\u00E9t\u00E9rinaire.",
"equity_transferred_eur": 663765.68,
"accounting_effective_date": "2024-07-01"
},
"subject_company": {
"kbo": "1015.868.627",
"name_full": "REVATIS VET",
"legal_form": "SRL"
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null
},
"summary_narrative": "La soci\u00E9t\u00E9 RevaTis (SA) envisage d\u0027apporter sa branche d\u0027activit\u00E9s de commercialisation de produits de m\u00E9decine r\u00E9g\u00E9n\u00E9rative v\u00E9t\u00E9rinaire et de R\u0026D en biotechnologie v\u00E9t\u00E9rinaire \u00E0 la soci\u00E9t\u00E9 RevaTis Vet (SRL). Ce projet d\u0027apport de branche d\u0027activit\u00E9s est \u00E9tabli conform\u00E9ment aux articles 12:10, 12:11 et 12:93 du Code des soci\u00E9t\u00E9s et des associations.",
"co_filed_documents": [],
"detected_real_type": "branch_contribution",
"referenced_correction": null,
"should_reroute_to_category": null
}| Legal nameFR | REVATIS VET |